Companion Diagnostics

Leverage the expertise behind one of the most successful companion diagnostic on the market to advance your companion diagnostic programs
  • Prototype test development (e.g. PD-L1 assay for lung carcinoma clinical study)
  • Platform independent approach
  • Expert consultation for:
    • Optimal antibody selection
    • Appropriate scoring scheme
    • Pivotal cut-off decisions
    • Strategy for testing & commercialization
  • Prospective testing of clinical samples (CLIA)
  • Accumulation of pivotal data
  • Validation reports for inclusion in regulatory filings
  • Logical & cost-effective approach

Connect With Us

Submit this form to start a conversation with Discovery to:
1

Begin IHC Service Project
2

Explore FFPE Inventory for IHC Analysis
3

Ask questions about our tissue biomarker solutions